Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Biological E

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

India's drug regulator has approved Takeda's Qdenga dengue vaccine, the first of its kind. This vaccine is expected to become available in India during the first half of 2027. Qdenga offers protection against all four dengue virus serotypes for individuals aged four to sixty. The vaccine demonstrated significant efficacy in…

The Economic Times

Biological E Limited partners with Bavarian Nordic to increase global access to Chikungunya Vaccine

This partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine, with the option to transfer the drug substance process at a later stage. Read further on Dynamite News:

Hyderabad’s Biological E. to make 50 million doses of Takeda’s dengue vaccine

Hyderabad’s Biological E. to make 50 million doses of Takeda’s dengue vaccine

Takeda and Hyderabad-based vaccine maker Biological E. have formed a strategic partnership to accelerate access to the Japanese firm’s QDENGA dengue vaccine (TAK-003) multi-dose vials.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Corbevax as booster dose to be available for adults from August 12

Price for end-users, including taxes and administrative charges, will be ₹400

Biological E. to invest ₹1,800 crore in Hyderabad’s Genome Valley

Aimed to ramp up manufacturing of vaccines, generic injectables, R&D

Corbevax gets nod as booster jab for Covaxin, Covishield recipients

HYDERABAD: Biological E Limited's Corbevax has emerged as India's first Covid-19 vaccine to receive approval as a heterologous booster dose for those aged 18 years and above, after six months of receiving the second dose of either Covaxin or Covishield.

The Times of India

COVID-19: Govt to expedite process of recognition of Biological E Corbevax by other countries

According to an internal document circulated to the members of the Empowered Group-5 on COVID-19 Vaccination, which will be meeting soon, some authorities abroad such as in Hong Kong have begun demanding vaccination certificates for children and only accept m-RNA based vaccines for them

inkl

Read news from The Economist, FT, and more,
with one subscription

Government panel recommends emergency use authorisation for Corbevax for 5-11 age group

Government panel recommends emergency use authorisation for Corbevax for 5-11 age group

The Subject Expert Committee has also recommended the grant of EUA to Cadila for their ZyCoV-D vaccine

Morning digest | Lok Sabha passes Criminal Procedure (Identification) Bill; India’s imports hit record $610 bn in 2021-22, and more

Morning digest | Lok Sabha passes Criminal Procedure (Identification) Bill; India’s imports hit record $610 bn in 2021-22, and more

A select list of stories to read before you start your day

Biological E. to receive mRNA vaccine tech from WHO

Biological E. to receive mRNA vaccine tech from WHO

Hub has potential to expand manufacturing capacity for other products beyond Covid vaccines

World moves from shortages to possible glut of Covid-19 vaccines

World moves from shortages to possible glut of Covid-19 vaccines

NEW YORK: After racing to build capacity and meet once seemingly insatiable orders for Covid-19 shots, the global vaccine industry is facing waning demand as many late-to-market producers fight over a slowing market.

The Times of India

Corbevax for 12-13 age group kids, Covaxin for 14 plus in Madhya Pradesh

Corbevax for 12-13 age group kids, Covaxin for 14 plus in Madhya Pradesh

BHOPAL: In Madhya Pradesh, children above 14 years (up to 15 years of age), will be administered Covaxin (BBV152). Children aged 12 to 13 years will be given Biological E’s Corbevax, according to state immunization in charge, Dr Santosh Shukla.

The Times of India

Rajasthan receives 30 lakh Corbevax doses for children aged 12-14

Rajasthan receives 30 lakh Corbevax doses for children aged 12-14

JAIPUR: The state has received 30 lakh doses of Biological E's Covid vaccine, Corbevax, for use in children aged between 12 to 14 years during a vaccination drive which will begin from March 16.

The Times of India

Biological E seeks EUA for Covid vaccine Corbevax for children in 5-12 age group: Official sources

Biological E seeks EUA for Covid vaccine Corbevax for children in 5-12 age group: Official sources

NEW DELHI: Hyderabad-based pharmaceutical company Biological E has applied for emergency use authorisation (EUA) for its Covid-19 vaccine Corbevax for the 5-12 year age group, official sources said on Wednesday.

The Times of India

Get all your
news in one place.

100's of premium titles.
One news app.

The Times of India

COVID vaccine for kids: Approval granted to COVID vaccine Corbevax for children between 12-18 years; here’s all we know

Drugs Controller General of India (DCGI) grants final approval to Biological E's COVID-19 vaccine Corbevax, for children between 12-18 years of age.

The Times of India

Mahima Datla to receive Federation of Asian Biotech Associations 2022 award

HYDERABAD: The Federation of Asian Biotech Associations (FABA) on Saturday said it will be conferring the Dr BS Bajaj Memorial FABA Special Award 2022 on Biological E Ltd’s managing director Mahima Datla in recognition of her efforts in augmenting the global fight against Covid-19 with Corbevax vaccine.

Biological E. MD and former IAS officer to get FABA awards

Awards to be given during BioAsia

1

People

K Chandrashekar Rao

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Bavarian Nordic

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

406,367 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play